Marco Ruella, MD

“Increasing the Therapeutic Index of Chimeric Antigen Receptor T cells for T cell Lymphomas”

Our goal is to bring the unquestioned power of CAR T cell therapy to bear on T cell lymphomas, a group of diseases with a poor prognosis and few treatment options. We will use the latest gene-editing tools to make an effective and safe immunotherapy.